0001209191-21-006934.txt : 20210202
0001209191-21-006934.hdr.sgml : 20210202
20210202183520
ACCESSION NUMBER: 0001209191-21-006934
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210129
FILED AS OF DATE: 20210202
DATE AS OF CHANGE: 20210202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Snisarenko John
CENTRAL INDEX KEY: 0001783264
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 21583213
MAIL ADDRESS:
STREET 1: C/O ALIMERA SCIENCES, INC.
STREET 2: 6120 WINDWARD PARKWAY, SUITE 290
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-29
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001783264
Snisarenko John
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109
PRINCETON
NJ
08540
0
1
0
0
Chief Commercial Officer
Common Stock
2021-01-29
4
A
0
11222
0.00
A
18222
D
Employee Stock Option (Right to Buy)
18.77
2021-01-29
4
A
0
50500
0.00
A
2031-01-28
Common Stock
50500
50500
D
Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
25% of the RSUs vest on January 29, 2022 and the remainder vest annually thereafter on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date.
Options granted on January 29, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 29, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date.
/s/ Brandon Fenn, Attorney-in-Fact
2021-02-02